细胞癌-话题@MedSci

#细胞癌#

1086篇内容 | 2787人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1979216, encodeId=217019e9216bc, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, objectType=article, longId=219167, objectId=456221916eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456221916eb9, replyNumber=0, likeNumber=78, createdTime=2022-06-21, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456221916eb9, moduleTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=456221916eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979207, encodeId=8e7c19e920760, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, objectType=article, longId=217963, objectId=568c21e96338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=568c21e96338, replyNumber=0, likeNumber=92, createdTime=2022-01-29, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=568c21e96338, moduleTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=568c21e96338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979194, encodeId=474e19e91941d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素, objectType=article, longId=217443, objectId=bacd21e4438e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacd21e4438e, replyNumber=0, likeNumber=78, createdTime=2022-09-07, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacd21e4438e, moduleTitle=Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bacd21e4438e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979176, encodeId=6da319e91769c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！, objectType=article, longId=214810, objectId=c1e621481097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e621481097, replyNumber=0, likeNumber=71, createdTime=2021-08-19, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e621481097, moduleTitle=Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e621481097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979306, encodeId=3fac19e93069c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！, objectType=article, longId=300902, objectId=92d130090243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92d130090243, replyNumber=0, likeNumber=84, createdTime=2022-03-29, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92d130090243, moduleTitle=Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92d130090243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979224, encodeId=3dc019e922457, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, objectType=article, longId=219491, objectId=16ac219491e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ac219491e4, replyNumber=0, likeNumber=74, createdTime=2022-08-29, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ac219491e4, moduleTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ac219491e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, objectType=article, longId=219191, objectId=02ce219191a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ce219191a0, replyNumber=0, likeNumber=60, createdTime=2022-02-04, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce219191a0, moduleTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ce219191a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979317, encodeId=f13319e931727, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）, objectType=article, longId=723571, objectId=265ee235713c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265ee235713c, replyNumber=0, likeNumber=63, createdTime=2022-08-09, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265ee235713c, moduleTitle=Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=265ee235713c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979183, encodeId=80ee19e91833f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=济民可信成功引进“索立德吉” 国内基底细胞癌药物获批上市, objectType=article, longId=215308, objectId=e71d21530816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e71d21530816, replyNumber=0, likeNumber=57, createdTime=2021-10-10, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e71d21530816, moduleTitle=济民可信成功引进“索立德吉” 国内基底细胞癌药物获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e71d21530816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979334, encodeId=d5a519e9334a5, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=CDD：抗精神病药五氟利多靶向DRD2抑制肾细胞癌生长, objectType=article, longId=727884, objectId=9f01e27884cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f01e27884cd, replyNumber=0, likeNumber=94, createdTime=2022-05-28, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f01e27884cd, moduleTitle=CDD：抗精神病药五氟利多靶向DRD2抑制肾细胞癌生长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f01e27884cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979296, encodeId=f2e919e929688, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, objectType=article, longId=299277, objectId=87e42992e798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87e42992e798, replyNumber=0, likeNumber=67, createdTime=2022-06-28, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87e42992e798, moduleTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87e42992e798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979347, encodeId=54e019e93477f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=中药汤剂可延长IV期食管鳞状细胞癌诊断后的寿命, objectType=article, longId=728913, objectId=a4cde28913a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4cde28913a3, replyNumber=0, likeNumber=86, createdTime=2022-07-31, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4cde28913a3, moduleTitle=中药汤剂可延长IV期食管鳞状细胞癌诊断后的寿命, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4cde28913a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979302, encodeId=e11919e93024d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, objectType=article, longId=300189, objectId=ad87300189e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad87300189e8, replyNumber=0, likeNumber=84, createdTime=2022-03-17, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad87300189e8, moduleTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad87300189e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979271, encodeId=0a6d19e92710a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异, objectType=article, longId=293862, objectId=e5bc2938625c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5bc2938625c, replyNumber=0, likeNumber=69, createdTime=2022-12-04, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5bc2938625c, moduleTitle=Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5bc2938625c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979246, encodeId=681219e924662, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=AJG：酒精性肝硬化患者戒酒对肝细胞癌风险的影响, objectType=article, longId=221166, objectId=25712211662e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25712211662e, replyNumber=0, likeNumber=50, createdTime=2022-06-29, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25712211662e, moduleTitle=AJG：酒精性肝硬化患者戒酒对肝细胞癌风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25712211662e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979266, encodeId=d42e19e92661a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, objectType=article, longId=293055, objectId=28ee293055ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ee293055ec, replyNumber=0, likeNumber=68, createdTime=2022-10-22, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ee293055ec, moduleTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ee293055ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979239, encodeId=55dd19e9239f9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Clin Cancer Res：晚期肾细胞癌免疫+靶向治疗后的无治疗生存期, objectType=article, longId=220642, objectId=32a82206422f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32a82206422f, replyNumber=0, likeNumber=73, createdTime=2021-12-09, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32a82206422f, moduleTitle=Clin Cancer Res：晚期肾细胞癌免疫+靶向治疗后的无治疗生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32a82206422f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979316, encodeId=5fef19e93168a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Front Oncol：局部晚期或转移性食管鳞状细胞癌患者在化疗基础上联合放疗可改善患者预后, objectType=article, longId=723550, objectId=0c6ae23550d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c6ae23550d2, replyNumber=0, likeNumber=60, createdTime=2022-10-04, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c6ae23550d2, moduleTitle=Front Oncol：局部晚期或转移性食管鳞状细胞癌患者在化疗基础上联合放疗可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c6ae23550d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979233, encodeId=4deb19e923330, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, objectType=article, longId=220048, objectId=533b22004862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=533b22004862, replyNumber=0, likeNumber=63, createdTime=2022-07-10, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=533b22004862, moduleTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=533b22004862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979261, encodeId=532119e926195, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=JGH：肿瘤负荷评分可以作为肝细胞癌患者接受经动脉化疗栓塞术的新预后标志物, objectType=article, longId=292063, objectId=557f29206341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=557f29206341, replyNumber=0, likeNumber=69, createdTime=2022-09-22, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=557f29206341, moduleTitle=JGH：肿瘤负荷评分可以作为肝细胞癌患者接受经动脉化疗栓塞术的新预后标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=557f29206341)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞癌

2020-05-29

qingting (审核中...)

前往app查看评论内容

#细胞癌#

更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗

2022-06-21

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效

2022-01-29

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素

2022-09-07

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！

2021-08-19

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！

2022-03-29

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效

2022-08-29

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性

2022-02-04

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）

2022-08-09

qingting (审核中...)

前往app查看评论内容

#细胞癌#

济民可信成功引进“索立德吉” 国内基底细胞癌药物获批上市

2021-10-10

qingting (审核中...)

前往app查看评论内容

#细胞癌#

CDD：抗精神病药五氟利多靶向DRD2抑制肾细胞癌生长

2022-05-28

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS

2022-06-28

qingting (审核中...)

前往app查看评论内容

#细胞癌#

中药汤剂可延长IV期食管鳞状细胞癌诊断后的寿命

2022-07-31

qingting (审核中...)

前往app查看评论内容

#细胞癌#

J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险

2022-03-17

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异

2022-12-04

qingting (审核中...)

前往app查看评论内容

#细胞癌#

AJG：酒精性肝硬化患者戒酒对肝细胞癌风险的影响

2022-06-29

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后

2022-10-22

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Clin Cancer Res：晚期肾细胞癌免疫+靶向治疗后的无治疗生存期

2021-12-09

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Front Oncol：局部晚期或转移性食管鳞状细胞癌患者在化疗基础上联合放疗可改善患者预后

2022-10-04

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性

2022-07-10

qingting (审核中...)

前往app查看评论内容

#细胞癌#

JGH：肿瘤负荷评分可以作为肝细胞癌患者接受经动脉化疗栓塞术的新预后标志物

2022-09-22

科室
- - 订阅+
  - 更多科室
工具
服务